Biologic therapy for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 3, Issue 2, 1997, Pages 95-113

  Sands, Bruce E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antisense oligonucleotides; Biologic therapy; Cell therapy; Crohn's disease; Gene therapy; Monoclonal antibodies; Ulcerative colitis

Indexed keywords

EID: 0002050773     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1002/ibd.3780030206     Document Type: Article

References (10)

1. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Si USA 1989;86:4220-4.
2. Co MS, Queen C. Humanized antibodies for therapy. Nature 1991;351:501-2.
3. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996;334:316-8.
4. Ledley FD. Somatic gene therapy in gastroenterology: approaches and applications. J Pediatr Gastroenterol Nutr 1992;14:328-37.
5. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 trangenic rats. J Exp Med 1994;180: 2359-64.
6. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
7. Nicolle MW, Nag B, Sharma SD, et al. Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest 1994;93:1361-9.
8. Brandeis JM, Sayegh MH, Gallon L, Blumberg RS, Carpenter CS. Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells. Gastroenterology 1994;107:1537-42.
9. Judge TA, Tang A, Turka LA. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996:15:38-49.
10. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.